Bonn SE, et al. - Researchers analyzed data from 11,886 men from the Carotene and Retinol Efficacy Trial (CARET, 1985–1996 with active follow-up through 2005), to examine the link between BMI (kg/m²) and prostate cancer risk. The participants included current and former heavy smokers. In CARET, which was a multicenter randomized, double-blind placebo-controlled chemoprevention trial, daily supplementation of 30 mg β-carotene+25 000 IU retinyl palmitate was tested as a primary preventive for lung cancer. Findings revealed that an increased risk of aggressive prostate cancer (not including Gleason 3+4 tumors) was observed in relation to having a BMI of at least 35 kg/m². However, BMI was not related to the risk of overall, aggressive disease including all Gleason 7, or nonaggressive prostate cancer